This is a Phase 1, open label, single dose study that will be conducted in adolescent participants with asthma where the participants will receive AZD8630 administered via dry powder inhaler.
The study will be comprised of:
* A screening period.
* A treatment period.
* A post treatment period.
* A final Follow-up visit.
